You are here

Development of a Smart REBOA Catheter

Award Information
Agency: Department of Defense
Branch: Defense Advanced Research Projects Agency
Contract: HR001122C0125
Agency Tracking Number: D2-2646
Amount: $1,499,308.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: HR001120S0019-26
Solicitation Number: HR001120S0019.I
Solicitation Year: 2020
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-06-06
Award End Date (Contract End Date): 2025-06-05
Small Business Information
16 Great Hollow Road
Hanover, NH 03755-1111
United States
DUNS: 072021041
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Michael Barton
 (603) 640-2476
Business Contact
 Patrick Magari
Phone: (603) 643-3800
Research Institution

Non-compressible torso hemorrhage (NCTH) is a leading cause of death when immediate access to a surgeon is not feasible. Resuscitative endovascular balloon occlusion of the aorta (REBOA), is an emerging and promising lifesaving procedure that involves placement and inflation of a small balloon catheter inside the aorta to control torso bleeding and to maintain blood pressure. However, irreversible organ damage below the balloon is unavoidable, and as a result, partial-REBOA approaches to enable controlled bleeding past the balloon are thought to be able to extend the time window for definitive treatment from less than one hour to up to two hours. We propose a smart-REBOA catheter that autonomously performs controlled bleeding to reduce irreversible damage to downstream organs while monitoring and maintaining hemodynamic status to preserve life. Importantly, our smart-REBOA catheter is designed to work seamlessly with our handheld Automated Vascular Access Device (AVAD) for semi-automated J-wire/catheter placement. In Phase I, we developed a preliminary design for a prototype system and demonstrated overall feasibility. In Phase II, we plan to develop a prototype system and evaluate its effectiveness with phantoms and swine experiments. In Phase III, we will validate the technology through clinical trials and will use that data to obtain FDA clearance.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government